Shots:

• Celltrion has presented the result of P-II study that showed that regimen of Truxima (375mg/m²) + lenalidomide (20mg- day 1-21- qd) + acalabrutinib (100mg- day 1-28- bid) (R2A) is well-tolerated and effective in relapsed/refractory aggressive B-cell lymphoma
• In the 13 patients who underwent disease assessment following the R2A regimen- ORR (69%) and CR (31%)- @6-mos. PFS (83%) and only one patient experienced disease progression after the initial objective response
• Throughout the study- out of 22 patients- dose reduction was performed in 3 and 1 patients for lenalidomide and acalabrutinib respectively due to hematologic toxicities. The data indicate that the R2A regimen was well tolerated in Korean r/r BCL patients- with initial analysis in non-GCB DLBCL patients showing a promising response

Click here to read full press release/ article 

Ref: Celltrion | Image: Celltrion